Innate Pharma (IPHYF) News Today → What President Biden's new law means for investors (From Stansberry Research) (Ad) Free IPHYF Stock Alerts $2.20 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth PotentialApril 3, 2024 | marketbeat.comInnate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%March 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)February 26, 2024 | benzinga.comInnate Pharma Stock (OTC:IPHYF), Insider Trading ActivityFebruary 4, 2024 | markets.businessinsider.comInnate Pharma SA (IPHYF) Receives a Hold from Kepler CapitalJanuary 11, 2024 | seekingalpha.comInnate Pharma: Worth A Deeper LookJanuary 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)January 4, 2024 | marketwatch.comInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on LacutamabDecember 28, 2023 | marketbeat.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Expands By 650.0%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,500 shares, a growth of 650.0% from the November 30th total of 600 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 22.5 days.December 19, 2023 | msn.comInnate Pharma and Sanofi to license natural killer cell engagerDecember 14, 2023 | markets.businessinsider.comBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory ProspectsNovember 27, 2023 | finance.yahoo.comInnate Pharma to Host Virtual KOL Event on LacutamabNovember 7, 2023 | finance.yahoo.comInnate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateOctober 27, 2023 | finance.yahoo.comInnate Pharma Announces Its Participation to Upcoming Investor ConferencesOctober 16, 2023 | finance.yahoo.comInnate Pharma Announces Abstracts Selected for ESMO Congress 2023October 5, 2023 | marketwatch.comInnate Pharma Shares Fall Premarket on FDA Partial Study HoldOctober 5, 2023 | msn.comRegulatory Hurdle For Innate Pharma's Blood Cancer StudiesOctober 5, 2023 | markets.businessinsider.comInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%September 22, 2023 | finance.yahoo.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023July 11, 2023 | finance.yahoo.comFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJuly 7, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023June 18, 2023 | markets.businessinsider.comKepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)June 8, 2023 | marketwatch.comADRs End Higher, Innate Pharma and Medigus Trade ActivelyJune 8, 2023 | marketwatch.comInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track DesignationMay 26, 2023 | finance.yahoo.comInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AMLMay 15, 2023 | finance.yahoo.comInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 CongressMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Innate Pharma (IPHA)May 10, 2023 | finance.yahoo.comInnate Pharma Reports First Quarter 2023 Financial Results and Business UpdateApril 26, 2023 | finance.yahoo.comInnate Pharma Establishes a New At-The-Market ("ATM") Program on NasdaqApril 12, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Innate Pharma (IPHA)April 6, 2023 | finance.yahoo.comInnate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-FApril 4, 2023 | markets.businessinsider.comInnate Pharma SA (IPHYF) Gets a Hold from Kepler CapitalApril 3, 2023 | msn.comInnate stock surges ~15% after license deal with TakedaApril 3, 2023 | finance.yahoo.comInnate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research ProgramMarch 29, 2023 | seekingalpha.comInnate Pharma S.A. 2022 Q4 - Results - Earnings Call PresentationMarch 28, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Innate Pharma (IPHA)March 23, 2023 | finance.yahoo.comInnate Pharma Reports Full Year 2022(1) Financial Results and Business UpdateMarch 13, 2023 | finance.yahoo.comInnate Pharma Provides Update on Silicon Valley Bank ExposureFebruary 21, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of February 1, 2023January 25, 2023 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell EngagersJanuary 25, 2023 | finance.yahoo.comInnate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell EngagersDecember 10, 2022 | finance.yahoo.comInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022December 9, 2022 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of December 1, 2022September 25, 2022 | markets.businessinsider.comKepler Capital Keeps Their Hold Rating on Innate Pharma SA (IPHYF)September 16, 2022 | seekingalpha.comInnate Pharma S.A. 2022 Q2 - Results - Earnings Call PresentationSeptember 16, 2022 | finance.yahoo.comEdited Transcript of IPH.PA earnings conference call or presentation 15-Sep-22 12:00pm GMTSeptember 15, 2022 | seekingalpha.comInnate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update TranscriptSeptember 15, 2022 | finance.yahoo.comInnate Pharma Reports First Half 2022 Financial Results and Business UpdateSeptember 8, 2022 | finance.yahoo.comInnate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. IPHYF Media Mentions By Week IPHYF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHYF News Sentiment▼-0.800.42▲Average Medical News Sentiment IPHYF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHYF Articles This Week▼10▲IPHYF Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Compugen News Genfit News Cellectis News Adverum Biotechnologies News X4 Pharmaceuticals News Cardiff Oncology News Elevation Oncology News Lineage Cell Therapeutics News Vaxart News Fennec Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPHYF) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.